EU/3/08/535

Table of contents

About

On 1 April 2008 , orphan designation (EU/3/08/535) was granted by the European Commission to Chiltern International Limited, United Kingdom, for humanised monoclonal antibody to the folate receptor alpha for the treatment of ovarian cancer.

The sponsorship was transferred to Eisai Europe Limited, United Kingdom, in June 2010. The sponsorship was transferred to Eisai GmbH, Germany, in September 2018.

The sponsor’s address was updated in August 2020.

Key facts

Active substance
Humanised monoclonal antibody to the folate receptor alpha
Disease / condition
Treatment of ovarian cancer
Date of first decision
01/04/2008
Outcome
Positive
EU designation number
EU/3/08/535

Sponsor's contact details

Edmund-Rumpler-Straße 3
60549 Frankfurt am Main
Germany
E-mail: kontakt@eisai.net

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating